Study of VX-770 on Desipramine
Completed · Phase 1
Conditions studied: In Development for Cystic Fibrosis
In brief
The objective of this study is to evaluate the effects of VX-770 on Desipramine
Key facts
- Study ID
- NCT01153542
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 24
- Starts
- 2010-06-01
- Expected to finish
- 2010-08-01
- Last updated by the study team
- 2010-12-09
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Subjects must be male or female and between 18 and 55 years of age
- Subject must have a body mass index (BMI) from 18 to 30 kg/m2
- Subject must be judged to be in good health
You may not qualify if…
- History of any illness that, in the opinion of the investigator or the subject's general practitioner, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject
- Subjects who have human immunodeficiency virus, hepatitis C, or active hepatitis B
- Female subjects and male subjects with female partner(s) who are pregnant, nursing, or planning to become pregnant during the study or within 90 days of the last dose of study drug
Where it is running
- Covance CRU, Inc. — Daytona Beach, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.